Patents Represented by Attorney Arnold & Porter LLP

Find this attorney in the Justia Lawyer Directory

  • Broccoli type having curds with detached florets
    Patent number: 8026416
    Abstract: The present invention includes broccoli plants with curds having detached florets and methods for obtained such broccoli plants. The present invention also provides reagents that can be used in methods for obtaining such broccoli plants.
    Type: Grant
    Filed: November 21, 2006
    Date of Patent: September 27, 2011
    Assignee: Seminis Vegatable Seeds, Inc.
    Inventors: Franciscus van den Bosch, Meinardus Petrus Boon
  • C3b antibodies and methods for the prevention and treatment of complement-associated disorders
    Patent number: 8012473
    Abstract: The present invention concerns antibodies to C3b and the prevention and treatment of complement-associated disorder using such antibodies.
    Type: Grant
    Filed: June 6, 2008
    Date of Patent: September 6, 2011
    Assignee: Genentech, Inc.
    Inventor: Menno Van Lookeren Campagne
  • Multi-generational pharmaceutically active protein production in corn
    Patent number: 8013210
    Abstract: The present invention provides multi-generational production methods for producing pharmaceutically active proteins and other proteins in corn. The present invention also provides methods for breeding corn capable of producing pharmaceutically active proteins or other proteins.
    Type: Grant
    Filed: April 27, 2004
    Date of Patent: September 6, 2011
    Assignee: Monsanto Technology LLC
    Inventors: Xavier Delannay, Dennis J. Dunphy, Fernando Gaitan-Gaitan, Thomas P. Jury
  • Prevention and treatment of complement-associated eye conditions
    Patent number: 8007791
    Abstract: The invention concerns the prevention and treatment of complement-associated eye conditions, such as choroidal neovascularization (CNV) and age-related macular degeneration (AMD), by administration of Factor D antagonists.
    Type: Grant
    Filed: May 22, 2008
    Date of Patent: August 30, 2011
    Assignee: Genentech, Inc.
    Inventors: Philip Hass, Yin Jianping, Kenneth Katschke, Jr., Micah Steffek, Christian Wiesmann, Menno Van Lookeren Campagne
  • Crystallization of antibody or fragment thereof
    Patent number: 8008447
    Abstract: The present disclosure concerns methods of crystallization and/or concentration of antibody or antibody fragments. The methods comprise contacting an antibody or antibody fragment with a solution comprising a salt of a divalent cation. Crystals and/or protein gels of antibody or antibody fragments are useful in compositions and formulations.
    Type: Grant
    Filed: July 22, 2005
    Date of Patent: August 30, 2011
    Assignee: Genentech, Inc.
    Inventors: Annette Marie Clasen Hagewiesche, Julie Fukami, Mary E. M. Cromwell, Rachel Bulotsky Dinges
  • Treatment of complement-associated disorders
    Patent number: 8007798
    Abstract: The present invention concerns a recently discovered macrophage specific receptor, CRIg, and its use in the prevention and treatment of complement-associated disorders, including complement-associated eye conditions, such as age-related macular degeneration (AMD) and choroidal neovascularization (CNV).
    Type: Grant
    Filed: October 12, 2005
    Date of Patent: August 30, 2011
    Assignee: Genentech, Inc.
    Inventors: Avi Ashkenazi, Karim Yussef Helmy, Sherman Fong, Audrey Goddard, Austin L. Gurney, Kenneth James Katschke, Jr., Menno Van Lookeren, William I. Wood
  • Method to identify disease resistant quantitative trait loci in soybean and compositions thereof
    Patent number: 7994395
    Abstract: The present invention is in the field of plant breeding and genetics, particularly as it pertains to the genus, Glycine. More specifically, the invention relates to a method for screening soybean plants containing one or more quantitative trait loci for disease resistance, species of Glycine having such loci and methods for breeding for and screening of Glycine with such loci. The invention further relates to the use of exotic germplasm in a breeding program.
    Type: Grant
    Filed: May 27, 2009
    Date of Patent: August 9, 2011
    Assignee: Monsanto Technology LLC
    Inventors: George James Baley, David Vincent Butruille, Samuel R. Eathington, Michael D. Haverdink, Warren M. Kruger, John Robert LeDeaux, Vergel C. Concibido, James Narvel, John W. Pitkin, John Tamulonis, Chongqing Xie
  • Detection of ErbB2 gene amplification to increase the likelihood of the effectiveness of ErbB2 antibody breast cancer therapy
    Patent number: 7993834
    Abstract: The invention provides a method for more effective treatment of patients susceptible to or diagnosed with tumors overexpressing ErbB, as determined by a gene amplification assay, with an ErbB antagonist. Such method comprises administering a cancer-treating dose of the ErbB antagonist, preferably in addition to chemotherapeutic agents, to a subject in whose tumor cells ErbB has been found to be amplified e.g., by fluorescent in situ hybridization. ErbB antagonists described include an anti-HER2 antibody. Pharmaceutical packaging for providing the components for such treatment is also provided.
    Type: Grant
    Filed: November 19, 2007
    Date of Patent: August 9, 2011
    Assignee: Genentech, Inc.
    Inventor: Robert D. Mass
  • Compositions and methods for treatment of cancer
    Patent number: 7982015
    Abstract: The present invention concerns compositions and methods for the treatment of disorders characterized by the overexpression of an LIV-1. More specifically, the compositions include DNA and amino acid sequences of an LIV-1, antibodies to an LIV-1, and methods for the treatment of a mammal susceptible to or diagnosed with cancer wherein an LIV-1 is overexpressed.
    Type: Grant
    Filed: May 2, 2005
    Date of Patent: July 19, 2011
    Assignee: Genentech, Inc.
    Inventors: Fred de Sauvage, Audrey Goddard, Austin L. Gurney, Jo-Anne Hongo, Victoria Smith
  • Isolation and identification of cross-reactive T cells
    Patent number: 7972848
    Abstract: Cross-reactive T cells recognizing both MBP93-105 and HHV-61-13 peptides represent a significant subset of T cells with some degree of TCR degeneracy. It appears that the recognition of the cross-reactive T cells has a less stringent requirement for the flanking residues of the two peptides. In contrast, these flanking residues are critical for the T cell recognition of mono-specific T cells. The association between HHV-6 and autoreactive immune responses to MBP indicates that cross-reactive T cells, peptides from the V-D-J region of the T cell receptor from autoreactive T cells, and antiviral agents may prevent or treat MS.
    Type: Grant
    Filed: August 19, 2009
    Date of Patent: July 5, 2011
    Assignee: Opexa Therapeutics, Inc.
    Inventor: Jingwu Z. Zang
  • Compositions and methods for the diagnosis and treatment of tumor
    Patent number: 7951546
    Abstract: The present invention is directed to compositions of matter useful for the diagnosis and treatment of tumor in mammals and to methods of using those compositions of matter for the same.
    Type: Grant
    Filed: May 29, 2008
    Date of Patent: May 31, 2011
    Assignee: Genetech, Inc.
    Inventors: Gretchen Frantz, Kenneth J. Hillan, Heidi Phillips, Paul Polakis, Susan D. Spencer, P. Mickey Williams, Thomas D. Wu, Zemin Zhang
  • Method to identify disease resistant quantitative trait loci in soybean and compositions thereof
    Patent number: 7951998
    Abstract: The present invention is in the field of plant breeding and genetics, particularly as it pertains to the genus, Glycine. More specifically, the invention relates to a method for screening soybean plants containing one or more quantitative trait loci for disease resistance, species of Glycine having such loci and methods for breeding for and screening of Glycine with such loci. The invention further relates to the use of exotic germplasm in a breeding program.
    Type: Grant
    Filed: May 24, 2007
    Date of Patent: May 31, 2011
    Assignee: Monsanto Technology LLC
    Inventors: George James Baley, David Vincent Butruille, Samuel R. Eathington, Michael D. Haverdink, Warren M. Kruger, John Robert LeDeaux, Vergel C. Concibido, James Narvel, John W. Pitkin, John Tamulonis, Chongqing Xie
  • Optical scanning system
    Patent number: 7951583
    Abstract: A scanning sensor system 100, methods and kits for use thereof including a switchable light source 102, a detector 106, a substrate 104 and a plurality of optical sensing sites 112 are provided. Substrate 104 is coupled to and in optical communication with switchable light source 102 and detector 106. Additionally, substrate 104 includes a plurality of substantially parallel excitation waveguides 108, and a plurality of substantially parallel collection waveguides 110, the excitation waveguides 108 and collection waveguides 110 crossing to form a two-dimensional array and optical communication with intersection regions 114 at each crossing. The plurality of optical sensing sites 112 are each in optical communication with an intersection region 114.
    Type: Grant
    Filed: March 8, 2007
    Date of Patent: May 31, 2011
    Assignee: PLC Diagnostics, Inc.
    Inventor: Reuven Duer
  • Article of manufacture
    Patent number: 7947650
    Abstract: The present invention relates to a method for the treatment of a cartilage disorder, including cartilage damaged by injury or degenerative cartilagenous disorders. The method involves contacting the cartilage with an IGF-1 analog with altered affinity for IGF-binding proteins (IGFBPs) or an IGFBP displacer peptide that prevents the interaction of an IGF with an IGFBP and does not bind to a human IGF receptor.
    Type: Grant
    Filed: October 30, 2007
    Date of Patent: May 24, 2011
    Assignee: Genentech, Inc.
    Inventors: Yvonne Man-Yee Chen, Ross G. Clark, Andrea G. Cochran, Yves Dubaquie, Paul J. Fielder, Ellen Filvaroff, Henry B. Lowman, Deborah L. Mortensen, Iain C. A. F. Robinson, Nicholas J. Skelton
  • Gene disruptions, compositions and methods relating thereto
    Patent number: 7947866
    Abstract: The present invention relates to transgenic animals, as well as compositions and methods relating to the characterization of gene function. Specifically, the present invention provides transgenic mice comprising disruptions in PRO194, PRO220, PRO241, PRO284, PRO331, PRO354, PRO355, PRO533, PRO541, PRO725, PRO937, PRO1014, PRO1120, PRO1182, PRO1325, PRO1382, PRO1410, PRO1555, PRO1556, PRO1760, PRO1787, PRO1868, PRO4326, PRO4332, PRO4346, PRO4400, PRO6003, PRO6094, PRO6244, PRO9820, PRO9828, PRO10274, PRO16090, PRO19644, PRO21340, PRO92165, PRO85143, PRO1124, PRO1026 or PRO23370 genes.
    Type: Grant
    Filed: October 18, 2005
    Date of Patent: May 24, 2011
    Assignee: Genentech, Inc.
    Inventor: Mary Jean Sparks
  • Modulators of neuronal regeneration
    Patent number: 7943329
    Abstract: The present invention provides methods and compositions related to CNS function and diseases.
    Type: Grant
    Filed: November 9, 2007
    Date of Patent: May 17, 2011
    Assignee: Genentech, Inc.
    Inventors: Jasvinder Atwal, Marc Tessier-Lavigne
  • Compositions and methods for the diagnosis and treatment of tumor
    Patent number: 7939268
    Abstract: The present invention is directed to compositions of matter useful for the diagnosis and treatment of tumor in mammals and to methods of using those compositions of matter for the same.
    Type: Grant
    Filed: May 15, 2007
    Date of Patent: May 10, 2011
    Assignee: Genentech, Inc.
    Inventors: Gretchen Frantz, Kenneth J. Hillan, Heidi Phillips, Paul Polakis, Susan D. Spencer, P. Mickey Williams, Thomas D. Wu, Zemin Zhang
  • Pantropic neurotrophic factors
    Patent number: 7935671
    Abstract: Pantropic neurotrophic factors which have multiple neurotrophic specificities are provided. The pantropic neurotrophic factors of the present invention are useful in the treatment of neuronal disorders. Nucleic acids and expression vectors encoding the pantropic neurotrophins are also provided.
    Type: Grant
    Filed: March 10, 2009
    Date of Patent: May 3, 2011
    Assignee: Genentech, Inc.
    Inventors: Roman Urfer, Leonard G. Presta, John W. Winslow
  • dUTP-based compositions for reducing primer-aggregate formations during nucleic acid amplification
    Patent number: 7932059
    Abstract: Methods and compositions are provided for enhanced specificity and sensitivity of amplification reaction mixtures. Compositions in accordance with the present invention provide for reduced formation of primer-aggregates during amplification reactions. Reaction mixes include dNTPs, where a portion of the dNTPs has been replaced with an unconventional nucleotide, e.g., dUTP. Unconventional nucleotide concentrations are typically between 10% to 50% of the concentration of one of the standard dNTP. In some compositions the unconventional nucleotide is dUTP which replaces from about 10% to about 50% of the dTTP in the dNTP mix.
    Type: Grant
    Filed: February 4, 2005
    Date of Patent: April 26, 2011
    Assignee: Qiagen North American Holdings
    Inventors: Ryan Smith Westberry, Lars-Erik Peters, Jessica Jaclyn Greenlee
  • Prescription medication bottle with a detachable cap
    Patent number: D639669
    Type: Grant
    Filed: August 12, 2009
    Date of Patent: June 14, 2011
    Assignee: Deborah Adler LLC
    Inventors: Deborah Adler, Duane Sawyer